DiaMedica Therapeutics (DMAC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

DMAC · Stock Price

USD 6.53+2.87 (+78.42%)

Market Cap: $348.1M

Historical price data

Market Cap: $348.1MFounded: 2000Employees: 11-50HQ: Minneapolis, United States

Sector Ranking#137 in Biologics / Biosimilars #4 in Synthetic Biology

Overview

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious ischemic disorders, with a mission to improve patient outcomes by targeting the underlying vascular injury. Its strategy is centered on DM199, a recombinant form of the human tissue kallikrein-1 protein, which aims to restore vascular function through a multi-faceted mechanism. The company has achieved key milestones, including positive interim Phase 2 data in preeclampsia and the advancement of a Phase 2/3 study in acute ischemic stroke, positioning it to address multi-billion dollar markets with no approved disease-modifying treatments.

Obstetrics & GynecologyNeurologyNephrology

Technology Platform

Recombinant human tissue kallikrein-1 (rhKLK1) platform designed to restore vascular health by promoting vasodilation, increasing collateral blood flow, and reducing inflammation through the kallikrein-kinin system.

Funding History

2

Total raised:$25M

PIPE$10MUndisclosedAug 15, 2021

IPO$15MUndisclosedFeb 15, 2019

Opportunities

DM199 addresses massive, underserved markets in preeclampsia and acute ischemic stroke where no disease-modifying therapies exist.

Success in either indication could create a multi-billion dollar product.

The extended 24-hour treatment window in stroke uniquely positions it to treat the ~80% of patients currently without options.

Risk Factors

High clinical development risk as value hinges on a single asset, DM199.

The company is pre-revenue and will require significant additional capital to complete late-stage trials, facing financing and dilution risk.

Regulatory pathways for first-in-class therapies in these indications are not fully established.

Competitive Landscape

In preeclampsia/FGR, the field is nascent with no approved therapies; competition includes early-stage programs targeting anti-angiogenic factors. In stroke, DM199's collateral circulation enhancement is unique versus failed neuroprotectants and limited-window reperfusion therapies, though other extended-window approaches are in development.